Factors and Outcomes Associated with MRCP Use prior to ERCP in Patients at High Risk for Choledocholithiasis

Table 3

Multivariable analysis of predictors of MRCP use in patients at high risk of choledocholithiasis.

Variable	Odd ratio	95% CI	value
Ascending cholangitis	0.72	(0.31, 1.7)	0.45
Bilirubin > 4	0.84	(0.26, 2.7)	0.77
CBD stone on US	0.09	(0.03, 0.28)	<0.0001
CBD dilatation and bilirubin 1.8–4	1.05	(0.30, 3.65)	0.93
Charlson comorbidity score	1.07	(0.86, 1.32)	0.53
Age	0.99	(0.97, 1.02)	0.61
Map < 65	1.08	(0.33, 3.56)	0.9
ICU status (ref. = ICU patient)	0.49	(0.19, 1.29)	0.15